Clinical Trial Update: Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity, safety, and 1-year persistence of antibodies after one or two doses of a meningococcal ACWY conjugate vaccine in healthy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal ACWY Conjugate Vaccine (Meningococcal conjugate vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Meningococcal Disease, Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2014-10-06